211 related articles for article (PubMed ID: 8962111)
1. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1.
Piao X; Paulson R; van der Geer P; Pawson T; Bernstein A
Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14665-9. PubMed ID: 8962111
[TBL] [Abstract][Full Text] [Related]
2. Specificity of the SH2 domains of SHP-1 in the interaction with the immunoreceptor tyrosine-based inhibitory motif-bearing receptor gp49B.
Wang LL; Blasioli J; Plas DR; Thomas ML; Yokoyama WM
J Immunol; 1999 Feb; 162(3):1318-23. PubMed ID: 9973385
[TBL] [Abstract][Full Text] [Related]
3. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
Shivakrupa R; Bernstein A; Watring N; Linnekin D
Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
[TBL] [Abstract][Full Text] [Related]
5. Leptin receptor activation of SH2 domain containing protein tyrosine phosphatase 2 modulates Ob receptor signal transduction.
Li C; Friedman JM
Proc Natl Acad Sci U S A; 1999 Aug; 96(17):9677-82. PubMed ID: 10449753
[TBL] [Abstract][Full Text] [Related]
6. SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain.
Kozlowski M; Larose L; Lee F; Le DM; Rottapel R; Siminovitch KA
Mol Cell Biol; 1998 Apr; 18(4):2089-99. PubMed ID: 9528781
[TBL] [Abstract][Full Text] [Related]
7. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells.
Piao X; Bernstein A
Blood; 1996 Apr; 87(8):3117-23. PubMed ID: 8605325
[TBL] [Abstract][Full Text] [Related]
8. Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation.
Hashimoto K; Matsumura I; Tsujimura T; Kim DK; Ogihara H; Ikeda H; Ueda S; Mizuki M; Sugahara H; Shibayama H; Kitamura Y; Kanakura Y
Blood; 2003 Feb; 101(3):1094-102. PubMed ID: 12393643
[TBL] [Abstract][Full Text] [Related]
9. Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1.
Paulson RF; Vesely S; Siminovitch KA; Bernstein A
Nat Genet; 1996 Jul; 13(3):309-15. PubMed ID: 8673130
[TBL] [Abstract][Full Text] [Related]
10. Genetic evidence that Shp-2 tyrosine phosphatase is a signal enhancer of the epidermal growth factor receptor in mammals.
Qu CK; Yu WM; Azzarelli B; Feng GS
Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8528-33. PubMed ID: 10411909
[TBL] [Abstract][Full Text] [Related]
11. A change in structural integrity of c-Kit mutant D816V causes constitutive signaling.
Raghav PK; Singh AK; Gangenahalli G
Mutat Res; 2018 Mar; 808():28-38. PubMed ID: 29482074
[TBL] [Abstract][Full Text] [Related]
12. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2.
Saxton TM; Henkemeyer M; Gasca S; Shen R; Rossi DJ; Shalaby F; Feng GS; Pawson T
EMBO J; 1997 May; 16(9):2352-64. PubMed ID: 9171349
[TBL] [Abstract][Full Text] [Related]
13. Establishment and characterization of pro-B cell lines from motheaten mutant mouse defective in SHP-1 protein tyrosine phosphatase.
Miyamoto A; Kunisada T; Yamazaki H; Miyake K; Nishikawa SI; Sudo T; Shultz LD; Hayashi SI
Immunol Lett; 1998 Sep; 63(2):75-82. PubMed ID: 9761368
[TBL] [Abstract][Full Text] [Related]
14. The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction.
Sun J; Pedersen M; Rönnstrand L
J Biol Chem; 2009 Apr; 284(17):11039-47. PubMed ID: 19265199
[TBL] [Abstract][Full Text] [Related]
15. The Shp-2 tyrosine phosphatase activates the Src tyrosine kinase by a non-enzymatic mechanism.
Walter AO; Peng ZY; Cartwright CA
Oncogene; 1999 Mar; 18(11):1911-20. PubMed ID: 10208413
[TBL] [Abstract][Full Text] [Related]
16. The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors.
Wu CJ; O'Rourke DM; Feng GS; Johnson GR; Wang Q; Greene MI
Oncogene; 2001 Sep; 20(42):6018-25. PubMed ID: 11593409
[TBL] [Abstract][Full Text] [Related]
17. Regulation of angiotensin II-induced JAK2 tyrosine phosphorylation: roles of SHP-1 and SHP-2.
Marrero MB; Venema VJ; Ju H; Eaton DC; Venema RC
Am J Physiol; 1998 Nov; 275(5):C1216-23. PubMed ID: 9814969
[TBL] [Abstract][Full Text] [Related]
18. The major SHP-1-binding, tyrosine-phosphorylated protein in macrophages is a member of the KIR/LIR family and an SHP-1 substrate.
Berg KL; Carlberg K; Rohrschneider LR; Siminovitch KA; Stanley ER
Oncogene; 1998 Nov; 17(19):2535-41. PubMed ID: 9824165
[TBL] [Abstract][Full Text] [Related]
19. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.
Jin Y; Ding K; Wang D; Shen M; Pan J
Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577
[TBL] [Abstract][Full Text] [Related]
20. Fyn kinase acts upstream of Shp2 and p38 mitogen-activated protein kinase to promote chemotaxis of mast cells towards stem cell factor.
Samayawardhena LA; Hu J; Stein PL; Craig AW
Cell Signal; 2006 Sep; 18(9):1447-54. PubMed ID: 16442778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
